End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients

Martinez, 2019, Biological basis for functional cure of chronic hepatitis B, J Viral Hepat, 75, 706, 10.1016/j.jhep.2021.05.013 Berg, 2017, Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study, J Hepatol, 67, 918, 10.1016/j.jhep.2017.07.012 Papatheodoridis, 2018, DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B, Antivir Ther, 23, 677, 10.3851/IMP3256 Ghany, 2020, Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad, Lancet Gastroenterol Hepatol, 5, 406, 10.1016/S2468-1253(19)30344-9 Hadziyannis, 2012, Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir, Gastroenterology, 143, 629, 10.1053/j.gastro.2012.05.039 Sonneveld, 2013, Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response, Clin Infect Dis, 56, 100, 10.1093/cid/cis859 Giersch, 2017, Serum HBV pgRNA as a clinical marker for cccDNA activity, J Hepatol, 66, 460, 10.1016/j.jhep.2016.09.028 van Bommel, 2018, Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B, J Infect Dis, 218, 1066, 10.1093/infdis/jiy270 Mak, 2018, Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection, Aliment Pharmacol Ther, 47, 43, 10.1111/apt.14376 Janssen, 2005, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0 Rijckborst, 2010, A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B, Am J Gastroenterol, 105, 1762, 10.1038/ajg.2010.186 Brouwer, 2015, Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study), Hepatology, 61, 1512, 10.1002/hep.27586 Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800 Farag, 2021, Hepatitis B virus RNA as early predictor for response to PEGylated interferon alfa in HBeAg negative chronic hepatitis B, Clin Infect Dis, 72, 202, 10.1093/cid/ciaa013 van Bommel, 2015, Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors, Hepatology, 61, 66, 10.1002/hep.27381 van Campenhout, 2018, Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment, Hepatology, 68, 839, 10.1002/hep.29872 van Campenhout, 2019, Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B, J Viral Hepat, 26, 1156, 10.1111/jvh.13117 Hsu, 2019, Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk, Aliment Pharmacol Ther, 49, 107, 10.1111/apt.15058 Liaw, 2020, Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat, Hepatology, 73, 843, 10.1002/hep.31525 Chi, 2016, Flares during long-term entecavir therapy in chronic hepatitis B, J Gastroenterol Hepatol, 31, 1882, 10.1111/jgh.13377 Flink, 2005, Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy, Gut, 54, 1604, 10.1136/gut.2004.062208 Chen, 2018, Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients, Clin Microbiol Infect, 24, 997, 10.1016/j.cmi.2017.12.013 Van Hees, 2018, Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes, Aliment Pharmacol Ther, 47, 1170, 10.1111/apt.14560 Bazinet, 2020, Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy, Gastroenterology, 158, 2180, 10.1053/j.gastro.2020.02.058 Sonneveld, 2020, Nucleic acid polymer therapy for hbv - strong hbsag decline but many unanswered questions, Gastroenterology, 160, 966, 10.1053/j.gastro.2020.06.097 Kaewdech, 2020, Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation, Liver Int, 40, 2961, 10.1111/liv.14606 Yuen, 2019, Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection, Gastroenterology, 156, 1392, 10.1053/j.gastro.2018.12.023 Sonneveld, 2020, Core inhibitor therapy for chronic hepatitis B, Lancet Gastroenterol Hepatol, 5, 99, 10.1016/S2468-1253(19)30325-5